Suppr超能文献

吸入布地奈德预防急进高原时急性高原病的疗效和安全性:一项随机对照试验的荟萃分析。

Efficacy and safety of inhaled budesonide on prevention of acute mountain sickness during emergent ascent: a meta-analysis of randomized controlled trials.

机构信息

Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, Nepal.

Mountain Medicine Society of Nepal, Kathmandu, Nepal.

出版信息

BMC Emerg Med. 2020 May 13;20(1):38. doi: 10.1186/s12873-020-00329-8.

Abstract

BACKGROUND

Acute Mountain Sickness (AMS) is a pathophysiologic process that occurs in non-acclimated susceptible individuals rapidly ascending to high-altitude. Barometric pressure falls at high altitude and it translates to a decreased partial pressure of alveolar oxygen (PAO2) and arterial oxygen (PaO2). A gradual staged ascent with sufficient acclimatization can prevent AMS but emergent circumstances requiring exposure to rapid atmospheric pressure changes - such as for climbers, disaster or rescue team procedures, and military operations - establishes a need for effective prophylactic medications. This systematic review and meta-analysis aim to analyze the incidence of AMS during emergent ascent of non-acclimatized individuals receiving inhaled budesonide compared to placebo.

METHODS

This current meta-analysis was conducted according to the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We searched PubMed, Google Scholar and Embase for relevant studies. The efficacy of budesonide in reducing incidence of AMS was evaluated by calculating the pooled ORs and 95% CIs. The efficacy of budesonide in maintaining hemoglobin-oxygen saturation was evaluated by calculating standard mean difference (SMD) and 95% confidence intervals.

RESULTS

We found that at high altitude, inhaled budesonide was effective in reducing the incidence of mild AMS [OR: 0.37; 95% CI, 0.14 to 0.9, p = 0.042] but was ineffective in reducing the incidence of severe AMS [OR: 0.46; 95% CI, 0.14 to 1.41, p = 0.17]. Inhaled budesonide was also effective in maintaining SpO2 (SMD: 0.47; 95% CI, 0.09 to 0.84, p = 0.014) at high altitude. However, it was not effective in maintaining or improving pulmonary function at high altitude. Systematic-review found no adverse effects of budesoide in the dose used for prophylaxis of AMS.

CONCLUSIONS

Our systematic review showed that prophylactic inhaled budesonide is effective in preventing mild AMS during emergency ascent but not effective in preventing severe AMS. Though statistically significant, authors recommend caution in interpretation of data and questions for further well designed randomized studies to evaluate the role of budesonide in prophylaxis of AMS during an emergent ascent.

摘要

背景

急性高原病(AMS)是一种发生在未经适应的易感个体中,迅速上升到高海拔地区的病理生理过程。高海拔地区的气压下降,导致肺泡氧分压(PAO2)和动脉氧分压(PaO2)降低。逐渐分阶段上升并充分适应可以预防 AMS,但需要暴露于快速气压变化的紧急情况,如登山者、灾难或救援团队程序以及军事行动,需要有效的预防性药物。本系统评价和荟萃分析旨在分析与安慰剂相比,吸入布地奈德对未经适应的个体在紧急上升期间 AMS 的发生率的影响。

方法

本荟萃分析根据系统评价和荟萃分析报告的首选报告项目指南进行。我们在 PubMed、Google Scholar 和 Embase 中搜索了相关研究。通过计算汇总 OR 和 95%CI,评估布地奈德在降低 AMS 发生率方面的疗效。通过计算标准均数差(SMD)和 95%置信区间来评估布地奈德维持血红蛋白-氧饱和度的疗效。

结果

我们发现,在高海拔地区,吸入布地奈德可有效降低轻度 AMS 的发生率[OR:0.37;95%CI,0.14 至 0.9,p=0.042],但不能降低重度 AMS 的发生率[OR:0.46;95%CI,0.14 至 1.41,p=0.17]。吸入布地奈德也能有效维持 SpO2(SMD:0.47;95%CI,0.09 至 0.84,p=0.014)在高海拔地区。然而,它在维持或改善高海拔地区的肺功能方面没有效果。系统评价发现,在预防 AMS 的剂量下,布地奈德没有不良反应。

结论

我们的系统评价表明,预防性吸入布地奈德在紧急上升期间预防轻度 AMS 是有效的,但对预防重度 AMS 无效。尽管具有统计学意义,但作者建议在解释数据时要谨慎,并提出进一步进行设计良好的随机研究的问题,以评估布地奈德在紧急上升期间预防 AMS 中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa3a/7222565/431b0bc64a4e/12873_2020_329_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验